Cytokinetics (NASDAQ:CYTK) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Cytokinetics, Incorporated (NASDAQ:CYTK). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Cytokinetics stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Cytokinetics Price Performance

Cytokinetics stock opened at $61.62 on Wednesday. The firm’s 50 day simple moving average is $71.13 and its 200-day simple moving average is $73.27. The company has a market cap of $7.67 billion, a P/E ratio of -8.53 and a beta of 0.41. Cytokinetics, Incorporated has a fifty-two week low of $54.30 and a fifty-two week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. The firm’s revenue was down 57.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.12) EPS. On average, analysts expect that Cytokinetics, Incorporated will post -5.98 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Robert Blum sold 97,926 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $69.33, for a total value of $6,789,209.58. Following the transaction, the chief executive officer directly owned 385,320 shares of the company’s stock, valued at approximately $26,714,235.60. This represents a 20.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. The trade was a 19.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 191,426 shares of company stock valued at $13,601,885. Insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CYTK shares. Needham & Company LLC increased their price target on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Citizens Jmp raised their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Barclays upped their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Finally, Truist Financial upped their price objective on shares of Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Eighteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $106.06.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional Phase 3 ACACIA-HCM analyses presented at the HFSA 2026 meeting provided more detail on aficamten’s ability to improve exercise performance in patients with non-obstructive hypertrophic cardiomyopathy. The results also supported dose titration and the drug’s safety profile, strengthening the potential commercial and regulatory case for Cytokinetics’ lead program. Cytokinetics Announces Additional ACACIA-HCM Data
• Positive Sentiment: Recent market coverage highlighted aficamten’s multi-domain benefits and the possibility that successful development could materially improve Cytokinetics’ long-term outlook. Analysts remain broadly constructive: the reported consensus rating is “Moderate Buy,” with an average price target of $106.06 versus the stock’s recent low-$60s trading range. Cytokinetics Average Price Target
• Neutral Sentiment: CEO Robert Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 plan. He retained 278,544 shares, so the transaction is a limited indicator of management sentiment, although it could create modest near-term pressure on the shares. SEC Form 4 Filing
• Negative Sentiment: Despite the clinical optimism, CYTK remains well below its 50-day and 200-day moving averages, and the company continues to report losses. Analysts expect a full-year loss, while quarterly revenue declined year over year, underscoring the execution, financing and commercialization risks that remain ahead of aficamten’s potential launch.

Institutional Trading of Cytokinetics

A number of institutional investors have recently added to or reduced their stakes in CYTK. GAMMA Investing LLC boosted its stake in Cytokinetics by 8.6% in the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 213 shares in the last quarter. Strs Ohio increased its stake in Cytokinetics by 2.4% during the 1st quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 300 shares in the last quarter. AlphaCentric Advisors LLC increased its stake in Cytokinetics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $370,000 after purchasing an additional 305 shares in the last quarter. Abel Hall LLC increased its stake in Cytokinetics by 10.5% during the 1st quarter. Abel Hall LLC now owns 4,050 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 384 shares in the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in Cytokinetics in the second quarter worth about $36,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.